Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Dornase alfa administered via jet nebulizer is indicated as a chronic respiratory medication for cystic fibrosis (CF) patients. Efficacy and safety of dornase alfa via an electronic nebulizer with vibrating membrane technology have not been formally assessed in randomized clinical trials.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Cyst. Fibros.

Title: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

ISSN (Electronic): 1873-5010

ISSN (Print): 1569-1993

Publication date (Electronic): Nov 2015

Volume: 14

Issue: 6

Affiliations

[1 ] Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA. Electronic address: gregory.sawicki@childrens.harvard.edu.

[2 ] 1 DNA Way, Genentech, Inc., South San Francisco, CA 94080, USA.

[3 ] Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, OH 44106, USA.

Article

Publisher Item ID: S1569-1993(15)00103-4

DOI: 10.1016/j.jcf.2015.04.003

PubMed ID: 25921451

SO-VID: 72961afb-b5d2-4a39-8ca1-1c67a6f33786

History

Keywords: Cystic fibrosis,Dornase alfa,Nebulizers

Data availability:

Keywords: Cystic fibrosis, Dornase alfa, Nebulizers

Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients.

Read this article at

Abstract

Related collections

Efficacy of Communicating Science

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 216

Cited by 12